Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hemothorax cost-effectiveness of therapy
Introduction
Cost-effective Therapy
Cost-effective Therapy
Avoiding surgery after treatment with any lytic agent was found to be 87% (95% CI, 81%-92%). Use of tissue plasminogen activator lead to 83% operative avoidance (95% CI, 71%-94%). Other, non-tissue plasminogen activator lytic agents lead to 87% surgery avoidance (95% CI, 82%-93%). Length of stay for patients on lytic therapy was 14.88 days (95% CI, 12.88-16.88) on average. Lytic Therapy could decrease the need for surgical intervention in patients with retained traumatic hemothorax. Randomized controlled trials are indicated to definitively assess the benefit of this therapy.[1]
References
References
- ↑ Hendriksen BS, Kuroki MT, Armen SB, Reed MF, Taylor MD, Hollenbeak CS (2019). “Lytic Therapy for Retained Traumatic Hemothorax: A Systematic Review and Meta-analysis”. Chest. 155 (4): 805–815. doi:10.1016/j.chest.2019.01.007. PMID 30664856.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani Joanna Ekabua, M.D. [2]